Changing Patterns of Bloodstream Infections in the Community and Acute Care Across 2 Coronavirus Disease 2019 Epidemic Waves: A Retrospective Analysis Using Data Linkage.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
24 08 2022
Historique:
received: 20 08 2021
pubmed: 2 10 2021
medline: 30 8 2022
entrez: 1 10 2021
Statut: ppublish

Résumé

We examined community- and hospital-acquired bloodstream infections (BSIs) in coronavirus disease 2019 (COVID-19) and non-COVID-19 patients across 2 epidemic waves. We analyzed blood cultures of patients presenting to a London hospital group between January 2020 and February 2021. We reported BSI incidence, changes in sampling, case mix, healthcare capacity, and COVID-19 variants. We identified 1047 BSIs from 34 044 blood cultures, including 653 (62.4%) community-acquired and 394 (37.6%) hospital-acquired. Important pattern changes were seen. Community-acquired Escherichia coli BSIs remained below prepandemic level during COVID-19 waves, but peaked following lockdown easing in May 2020, deviating from the historical trend of peaking in August. The hospital-acquired BSI rate was 100.4 per 100 000 patient-days across the pandemic, increasing to 132.3 during the first wave and 190.9 during the second, with significant increase in elective inpatients. Patients with a hospital-acquired BSI, including those without COVID-19, experienced 20.2 excess days of hospital stay and 26.7% higher mortality, higher than reported in prepandemic literature. In intensive care, the BSI rate was 421.0 per 100 000 intensive care unit patient-days during the second wave, compared to 101.3 pre-COVID-19. The BSI incidence in those infected with the severe acute respiratory syndrome coronavirus 2 Alpha variant was similar to that seen with earlier variants. The pandemic have impacted the patterns of community- and hospital-acquired BSIs, in COVID-19 and non-COVID-19 patients. Factors driving the patterns are complex. Infection surveillance needs to consider key aspects of pandemic response and changes in healthcare practice.

Sections du résumé

BACKGROUND
We examined community- and hospital-acquired bloodstream infections (BSIs) in coronavirus disease 2019 (COVID-19) and non-COVID-19 patients across 2 epidemic waves.
METHODS
We analyzed blood cultures of patients presenting to a London hospital group between January 2020 and February 2021. We reported BSI incidence, changes in sampling, case mix, healthcare capacity, and COVID-19 variants.
RESULTS
We identified 1047 BSIs from 34 044 blood cultures, including 653 (62.4%) community-acquired and 394 (37.6%) hospital-acquired. Important pattern changes were seen. Community-acquired Escherichia coli BSIs remained below prepandemic level during COVID-19 waves, but peaked following lockdown easing in May 2020, deviating from the historical trend of peaking in August. The hospital-acquired BSI rate was 100.4 per 100 000 patient-days across the pandemic, increasing to 132.3 during the first wave and 190.9 during the second, with significant increase in elective inpatients. Patients with a hospital-acquired BSI, including those without COVID-19, experienced 20.2 excess days of hospital stay and 26.7% higher mortality, higher than reported in prepandemic literature. In intensive care, the BSI rate was 421.0 per 100 000 intensive care unit patient-days during the second wave, compared to 101.3 pre-COVID-19. The BSI incidence in those infected with the severe acute respiratory syndrome coronavirus 2 Alpha variant was similar to that seen with earlier variants.
CONCLUSIONS
The pandemic have impacted the patterns of community- and hospital-acquired BSIs, in COVID-19 and non-COVID-19 patients. Factors driving the patterns are complex. Infection surveillance needs to consider key aspects of pandemic response and changes in healthcare practice.

Identifiants

pubmed: 34596212
pii: 6378783
doi: 10.1093/cid/ciab869
pmc: PMC9402624
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1082-e1091

Subventions

Organisme : Medical Research Council
ID : MR/T005254/1
Pays : United Kingdom

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Clin Microbiol Infect. 2021 Nov;27(11):1658-1665
pubmed: 34481722
BMC Infect Dis. 2021 Jun 11;21(1):556
pubmed: 34116643
BMJ. 2020 May 18;369:m1983
pubmed: 32423901
Br J Nurs. 2020 Nov 26;29(21):1238-1240
pubmed: 33242266
Lancet Microbe. 2021 Aug;2(8):e354-e365
pubmed: 34100002
Clin Microbiol Infect. 2021 Jan;27(1):9-11
pubmed: 32979569
Emerg Infect Dis. 2021 Apr;27(4):1234-1237
pubmed: 33565961
Lancet Reg Health Eur. 2021 Jun 08;7:100144
pubmed: 34557845
J Antimicrob Chemother. 2020 Jul 1;75(7):1681-1684
pubmed: 32433765
BMJ. 2020 Mar 20;368:m1117
pubmed: 32198166
BMJ Open. 2016 Feb 19;6(2):e010134
pubmed: 26895985
Infect Control Hosp Epidemiol. 2020 Mar;41(3):342-354
pubmed: 31898557

Auteurs

Nina J Zhu (NJ)

National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, United Kingdom.

Timothy M Rawson (TM)

National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, United Kingdom.
Imperial College Healthcare National Health Service Trust, Imperial College London, London, United Kingdom.
Centre for Antimicrobial Optimisation, Imperial College London, London, United Kingdom.

Siddharth Mookerjee (S)

Imperial College Healthcare National Health Service Trust, Imperial College London, London, United Kingdom.

James R Price (JR)

National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, United Kingdom.
Imperial College Healthcare National Health Service Trust, Imperial College London, London, United Kingdom.

Frances Davies (F)

Imperial College Healthcare National Health Service Trust, Imperial College London, London, United Kingdom.

Jonathan Otter (J)

National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, United Kingdom.
Imperial College Healthcare National Health Service Trust, Imperial College London, London, United Kingdom.

Paul Aylin (P)

National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, United Kingdom.
Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdomand.

Russell Hope (R)

Division of Healthcare Associated Infection and Antimicrobial Resistance, Public Health England, London, United Kingdom.

Mark Gilchrist (M)

National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, United Kingdom.
Imperial College Healthcare National Health Service Trust, Imperial College London, London, United Kingdom.
Centre for Antimicrobial Optimisation, Imperial College London, London, United Kingdom.

Yeeshika Shersing (Y)

Imperial College Healthcare National Health Service Trust, Imperial College London, London, United Kingdom.

Alison Holmes (A)

National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, United Kingdom.
Imperial College Healthcare National Health Service Trust, Imperial College London, London, United Kingdom.
Centre for Antimicrobial Optimisation, Imperial College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH